Abstract
The transcatheter arterial infusion (TAI) and transcatheter arterial embolization (TAE) have good effects on a variety of solid tumors. In the treatment of liver cancer, they are more effective, especially. Currently, TAI and TAE not only are main methods in the treatment of unresectable colorectal cancer liver metastases but also play important roles in the adjuvant treatment and new adjuvant therapy of colorectal cancer liver metastases [1–4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kelly RJ, Kemeny NE, Leonard GD. Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer. 2005;5(3):166–74.
Pasetto LM, Merenda R, Pilati P, et al. Hepatic metastases of colorectal cancer: locoregional intra-arterial treatment. Anticancer Res. 2006;26(6C):4785–92.
Dizon DS, Schwartz J, Kemeny N. Chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. Surg Oncol Clin N Am. 2008;17(4):759–71.
Tsutsumi S, Yamaguchi S, Tsuboi K, et al. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer. Hepatogastroenterology. 2008;55(85):1419–22.
Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88(5):252–8.
Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer. 1996;78(8):1639–45.
Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395–403.
Dzodic R, Gomez-Abuin G, Rougier P, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs. 2004;15(6):647–50.
van Riel JM, van Groeningen CJ, Kedde MA, et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res. 2002;8(2):405–12.
Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.
Kemeny MM, Adak S, Gray B, Macdonald JS, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy – an intergroup study. J Clin Oncol. 2002;20(6):1499–505.
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039–48.
Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62(2):195–201.
Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol. 2003;14(10):1537–42.
Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.
Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009;27(2):199–205.
Ricke J, Hildebrandt B, Miersch A, et al. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol. 2004;15(8):825–33.
Iguchi T, Inaba Y, Arai Y, et al. Radiologic removal and replacement of port-catheter systems for hepatic arterial infusion chemotherapy. AJR Am J Roentgenol. 2006;187(6):1579–84.
Tono T, Ukei T, Masutani S. Management of hepatic arterial infusion port following prophylactic regional chemotherapy in patients who have undergone curative resection of colorectal liver metastases. Surg Today. 2003;33(9):679–83.
Sameshima S, Horikoshi H, Motegi K, et al. Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters. Eur J Surg Oncol. 2007;33(6):741–5.
Zanon C, Grosso M, Clara R, et al. Percutaneous implantation of arterial Port-a-cath via trans-subclavian access. Anticancer Res. 1999;19:5667–71.
Herrmann KA, Waggershauser T, Sittek H, et al. Liver intraarterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems. Radiology. 2000;215:294–9.
Yamagami T, Terayama K, Yoshimatsu R, et al. Use of N-butyl cyanoacrylate in implantation of a port-catheter system for hepatic arterial infusion chemotherapy with the fixed-catheter-tip method: is it necessary? AJR Am J Roentgenol. 2008;191(5):1523–9.
Hamada A, Yamakado K, Nakatsuka A, et al. Repeated hepatic arterial infusion chemotherapy using an implanted port system in patients with unresectable malignant liver neoplasms: significant factors affecting early hepatic arterial occlusion. Oncol Rep. 2003;10(6):1821–7.
Wood BJ, Ramkaransingh JR, Fojo T, et al. Percutaneous tumor ablation with radiofrequency. Cancer. 2002;94(2):443–51.
Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities—part I. J Vasc Interv Radiol. 2001;12(9):1021–32.
Rachbauer F, Mangat J, Bodner G, et al. Heat distribution and heat transport in bone during radiofrequency catheter ablation. Arch Orthop Trauma Surg. 2003;123(2–3):86–90.
Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities—part II. J Vasc Interv Radiol. 2001;12(10):1135–48.
Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237(2):171–9.
Allgaier HP, Galandi D, Zuber I, et al. Radiofrequency thermal ablation of hepatocellular carcinoma. Dig Dis. 2001;19(4):301–10.
Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol. 1998;170(4):1015–22.
Haemmerich D, Wright AW, Mahvi DM, et al. Hepatic bipolar radiofrequency ablation creates coagulation zones close to blood vessels: a finite element study. Med Biol Eng Comput. 2003;41(3):317–23.
Baere TD, Denys A, Wood BJ, et al. Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. AJR Am J Roentgenol. 2001;176(1):187–92.
Kettenbach J, Kostler W, Rucklinger E, et al. Percutaneous saline-enhanced radiofrequency ablation of unresectable hepatic tumors: initial experience in 26 patients. AJR Am J Roentgenol. 2003;180(6):1537–45.
Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–51.
McGrane S, McSweeeney SE, Maher MM. Which patients will benefit from percutaneous radiofrequency ablation of colorectal cancer metastases ? A critically appraised topic. Abdom Imaging. 2008;33:48–53.
Solbiati L, Livrhagi T, Goldberg SN, et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221:159–66.
Siperstein A, Berber E, Ballerm N, Rikesh T. Survival after radiofrequency ablation of colorectal metastases: 10-year-experience. Ann Surg. 2007;246:559–67.
Veltri A, Sacchetto P, Tosetti I, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol. 2008;31:948–56.
Ruers T, van Coevorden F, Pierie JPJ, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): interim results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol. 2008, ASCO annual meeting proceedings; 2008, 26:4012.
Livraghi T, Solbiati L, Meloni F, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. Cancer. 2003;97:3027–35.
Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg. 2002;137:833–40.
Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–22.
Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242:158–71.
Oka M, Hazama S, Suzuki M, et al. Depression of cytotoxicity of nonparenchymal cells in the liver after surgery. Surgery. 1994;116:877–82.
Wissniowski TT, Hansler J, Neureiter D, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res. 2003;63:6496–500.
Zerbini A, Pilli M, Penna A, Pelosi G, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006;66:1139–46.
Oshowo A, Gillams A, Harrison E, et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003;90(10):1240–3.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25.
Mulier S, Ni Y, Jamart J, et al. Radiofrequency ablation versus resection for respectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol. 2008;15:144–57.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Dordrecht and People's Medical Publishing House
About this chapter
Cite this chapter
Wang, J., Chen, Y. (2017). Interventional Treatment of Liver Metastasis of Colorectal Cancer. In: Qin, X., Xu, J., Zhong, Y. (eds) Multidisciplinary Management of Liver Metastases in Colorectal Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7755-1_18
Download citation
DOI: https://doi.org/10.1007/978-94-017-7755-1_18
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7753-7
Online ISBN: 978-94-017-7755-1
eBook Packages: MedicineMedicine (R0)